Top 10 Insider Buys April 2026: Where CEOs Are Investing Millions Now 📈
When CEOs, directors, and 10% owners buy millions of dollars of their own stock, it’s worth paying attention. Here are the top insider buys of April 2026—and why MGM, PANW, AHCO, and others stand out.
Phreesia (PHR): Profitable… Then Crushed — Why Insiders Are Loading Up
Phreesia just hit profitability—and got punished for it. With insiders loading up and institutions fully committed, is this a classic overreaction or a value trap? Let’s decode the dip.
IPX Stock: America’s Titanium Comeback—or a Costly Experiment? 🦾
IperionX is betting on a U.S. titanium comeback. With government backing and disruptive tech, the upside is huge—but so are the risks.
2 comments
|
📈 CME Group Stock Analysis 2026: A Near-Monopoly at Record Highs
CME Group is the “house that always wins” in financial markets. A dominant, cash-generating business—but at current prices, patience may pay off.
PANW Stock Analysis 2026: Why CEO Nikesh Arora Just Bet $10M on Palo Alto Networks 🛡️
PANW is the “Microsoft of cybersecurity”—dominant, profitable, and growing fast. But with premium valuation and heavy institutional ownership, is now the right time to buy?
Lululemon (LULU): 68% Off — Bargain or Value Trap? 🧘
Lululemon (LULU) has fallen sharply from its highs, but insider buying and international growth suggest opportunity. Is this a contrarian buy—or a value trap in disguise?
CORT Stock 2026: FDA Rejection, Insider Buying… and a Brewing Short Squeeze?
Corcept Therapeutics just got hit with an FDA rejection—but insiders are buying millions and short interest is surging. With a profitable base business and major 2026 catalysts ahead, CORT may be one of the most explosive “binary bets” in biotech today.
BLDR Stock Analysis 2026: Why Paul Levy’s $4.3M Bet Makes Builders FirstSource Look Like a Strong Buy
Builders FirstSource may be the fixer-upper of the industrial sector: messy near term, but structurally strong. Here’s why BLDR’s insider buying, buybacks, and rebound potential make it worth a close look.
MTN Stock Analysis 2026: Why Rob Katz’s $5M Buy Signals a Peak Opportunity in Vail Resorts
Vail Resorts (MTN) just endured one of the worst snowfall seasons in decades—yet insiders are buying millions in stock. With a powerful Epic Pass model, heavy institutional ownership, and rising short interest, this mountain stock may be setting up for a contrarian move.
ROCK Stock Analysis 2026: Is Gibraltar Industries Undervalued by 71% After the OmniMax Deal?
Gibraltar Industries may not be glamorous, but the company sits at the heart of housing, infrastructure, and agtech. With insider buying, a massive OmniMax acquisition, and valuations near historic lows, ROCK could be one of the market’s most overlooked industrial value plays.